HMPL-653 / Hutchmed - LARVOL DELTA

HUTCHMED Highlights Clinical Data to be Presented at…the CSCO Annual Meeting 2025 (GlobeNewswire) - "Clinical data of HMPL-653, a novel, selective and potent CSF-1R inhibitor, from a first-in-human Phase I study in patients with tenosynovial giant cell tumor in China will be presented for the first time at the CSCO Annual Meeting 2025."

P1 data • Tenosynovial Giant Cell Tumor

HMPL-653, a highly potent and selective CSF-1R inhibitor, targeting both tumor cells and tumor microenvironment. (AACR-NCI-EORTC 2023) - No abstract available

Biomarker • Tumor cell • Tumor microenvironment • Oncology

Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT (clinicaltrials.gov) - P1 | N=113 | Recruiting | Sponsor: Hutchison Medipharma Limited

New P1 trial • Giant Cell Tumor of Bone • Immunology • Oncology • Solid Tumor • Tenosynovial Giant Cell Tumor

HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China (GlobeNewswire) - "HUTCHMED (China) Limited...announces that it has initiated a Phase I trial in China of HMPL-653, an investigational novel, highly selective, and potent colony-stimulating factor 1 receptor ('CSF-1R') inhibitor. The first patient received their first dose on January 18, 2022. The Phase I trial is a multicenter, open-label, single-arm study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HMPL-653 in the treatment of patients with advanced or metastatic solid tumors and tenosynovial giant cell tumors ('TGCT')."

Trial status • Oncology • Solid Tumor